Search research articles
Contact Us
Filters
Showing results (51-60 of 73) with videos related to
Page
of 8
Sort By:
British Journal of Haematology
|
February 18, 2017
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience
Nicola Maciocia, Andrew Melville, Simon Cheesman, et al.
Haematologica
|
December 9, 2008
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells
Jose L R Brito, Brian Walker, Matthew Jenner, et al.
Chemical Science
|
July 12, 2019
An unusual <i>Burkholderia gladioli</i> double chain-initiating nonribosomal peptide synthetase assembles 'fungal' icosalide antibiotics
Matthew Jenner, Xinyun Jian, Yousef Dashti, et al.
British Journal of Haematology
|
May 22, 2020
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy
Gordon Cook, A John Ashcroft, Guy Pratt, et al.
Blood
|
October 20, 2020
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
Meletios Dimopoulos, Sara Bringhen, Pekka Anttila, et al.
Blood
|
December 23, 2022
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial
Aikaterini Panopoulou, David A Cairns, Amy Holroyd, et al.
Nucleic Acids Research
|
April 14, 2022
Microarray screening reveals two non-conventional SUMO-binding modules linked to DNA repair by non-homologous end-joining
Maria Jose Cabello-Lobato, Matthew Jenner, Metztli Cisneros-Aguirre, et al.
Bone Marrow Transplantation
|
January 10, 2024
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial
Ruth M de Tute, Gordon Cook, David A Cairns, et al.
Leukemia
|
September 8, 2020
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Meletios Dimopoulos, Katja Weisel, Philippe Moreau, et al.
Nature Chemistry
|
September 25, 2019
Structural basis for chain release from the enacyloxin polyketide synthase
Simone Kosol, Angelo Gallo, Daniel Griffiths, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 73) with videos related to
Sort By:
Page
of 8
British Journal of Haematology
|
February 18, 2017
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience
Nicola Maciocia, Andrew Melville, Simon Cheesman, et al.
Haematologica
|
December 9, 2008
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells
Jose L R Brito, Brian Walker, Matthew Jenner, et al.
Chemical Science
|
July 12, 2019
An unusual <i>Burkholderia gladioli</i> double chain-initiating nonribosomal peptide synthetase assembles 'fungal' icosalide antibiotics
Matthew Jenner, Xinyun Jian, Yousef Dashti, et al.
British Journal of Haematology
|
May 22, 2020
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy
Gordon Cook, A John Ashcroft, Guy Pratt, et al.
Blood
|
October 20, 2020
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
Meletios Dimopoulos, Sara Bringhen, Pekka Anttila, et al.
Blood
|
December 23, 2022
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial
Aikaterini Panopoulou, David A Cairns, Amy Holroyd, et al.
Nucleic Acids Research
|
April 14, 2022
Microarray screening reveals two non-conventional SUMO-binding modules linked to DNA repair by non-homologous end-joining
Maria Jose Cabello-Lobato, Matthew Jenner, Metztli Cisneros-Aguirre, et al.
Bone Marrow Transplantation
|
January 10, 2024
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial
Ruth M de Tute, Gordon Cook, David A Cairns, et al.
Leukemia
|
September 8, 2020
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Meletios Dimopoulos, Katja Weisel, Philippe Moreau, et al.
Nature Chemistry
|
September 25, 2019
Structural basis for chain release from the enacyloxin polyketide synthase
Simone Kosol, Angelo Gallo, Daniel Griffiths, et al.
Page
of 8